Feras Hantash

OncoKB: A Precision Oncology Knowledge Base

Debyani Chakravarty, Jianjiong Gao, Sarah Phillips et al. · JCO Precision Oncology · 2017 · 2.7K citations

Medicine, Biomedical Informatics, Oncology +17

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk

Amit Khera, Brendan M. Everett, Michael P. Caulfield et al. · Circulation · 2013 · 447 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.

Weiping Yu, Qiao Liao, Feras Hantash et al. · PubMed · 2001 · 124 citations

Life Sciences, Cell Biology, Oncology +16

FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: Insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States

Feras Hantash, Dana Goos, Beryl Crossley et al. · Genetics in Medicine · 2010 · 106 citations · Full text

Medicine, Genetics, Gynecology +14

Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: Implications for fragile X syndrome carrier and newborn screening

Feras Hantash, Dana G. Goos, David Tsao et al. · Genetics in Medicine · 2010 · 83 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17